Last reviewed · How we verify

Rapid sedation

University of Southern Denmark · Phase 3 active Small molecule

Rapid sedation induces quick-onset central nervous system depression to facilitate anesthesia or acute sedation.

Rapid sedation induces quick-onset central nervous system depression to facilitate anesthesia or acute sedation. Used for Rapid sedation for anesthesia or acute medical procedures.

At a glance

Generic nameRapid sedation
SponsorUniversity of Southern Denmark
ModalitySmall molecule
Therapeutic areaAnesthesia/Sedation
PhasePhase 3

Mechanism of action

The drug is designed to achieve sedation with a rapid onset profile, likely through GABAergic or other CNS-depressant pathways. The specific molecular mechanism is not publicly detailed in available literature for this University of Southern Denmark investigational program.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: